Behr T M, Becker W S, Sharkey R M, Juweid M E, Dunn R M, Bair H J, Wolf F G, Goldenberg D M
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Newark, New Jersey 07103-2763, USA.
J Nucl Med. 1996 May;37(5):829-33.
The renal uptake of radiolabeled antibody fragments and peptides presents a problem in radioimmunodetection and therapy, compromising lesion sensitivity, especially with intracellularly-retained isotopes. Previously, we showed that cationic amino acids and their derivatives are capable of significantly reducing kidney uptake in animals. We report our initial clinical results of successful renal uptake reduction in five patients who underwent cancer radioimmunodetection with 99mTc-anti-CEA Fab' fragments.
The patients were infused with two liters of a commercially-available nutritive amino acid solution (containing approximately 2.25 g/liter lysine-glutamate and 2.50 g/liter arginine), whereas 75 control patients received the same volume of saline (quantification of organ and tumor kinetics from conjugate whole-body views by ROI technique).
The renal uptake in the amino acid group was significantly lower (p<0.05) than in the control group (11.1 +/- 2.0% injected dose versus 17.7 +/- 7.0% injected dose at 24 hr postinjection), whereas the uptake of all other organs remained unaffected. Gel filtration chromatography of the urine taken from amino-acid-treated patients showed that a significantly higher amount of excreted activity was bound to intact Fab' (53% of excreted activity) in contrast to only less than 10% in the control group.
The renal uptake of monoclonal antibody fragments in patients can be reduced significantly by amino acid infusion, even at considerably lower doses than those that were safe and effective in animals. As was found in animals, the mechanism seems to rely on an inhibition of the re-absorption of tubularly-filtered proteins by the proximal tubule cells. These results encourage further clinical trials to lower the renal uptake experienced in radioimmunodetection, as well as in therapeutic trials with antibody fragments and peptides.
放射性标记的抗体片段和肽在肾脏中的摄取在放射免疫检测和治疗中是一个问题,会损害病变敏感性,特别是对于细胞内保留的同位素。此前,我们表明阳离子氨基酸及其衍生物能够显著降低动物肾脏的摄取。我们报告了5例接受99mTc-抗CEA Fab'片段癌症放射免疫检测患者成功降低肾脏摄取的初步临床结果。
给患者输注两升市售营养氨基酸溶液(含有约2.25g/升赖氨酸-谷氨酸和2.50g/升精氨酸),而75例对照患者接受相同体积的生理盐水(通过ROI技术从共轭全身视图定量器官和肿瘤动力学)。
氨基酸组的肾脏摄取明显低于对照组(p<0.05)(注射后24小时为11.1±2.0%注射剂量,而对照组为17.7±7.0%注射剂量),而所有其他器官的摄取不受影响。对氨基酸治疗患者尿液进行凝胶过滤色谱分析表明,与对照组仅不到10%相比,排泄活性中与完整Fab'结合的量显著更高(排泄活性的53%)。
通过输注氨基酸可显著降低患者体内单克隆抗体片段的肾脏摄取,即使剂量远低于在动物中安全有效的剂量。正如在动物中发现的那样,其机制似乎依赖于近端小管细胞对经肾小管滤过的蛋白质重吸收的抑制。这些结果鼓励进一步开展临床试验,以降低放射免疫检测以及抗体片段和肽治疗试验中出现的肾脏摄取。